May 30, 2016 / by / News
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)
Read more
SolAeroMed Investment Announcement
December 6, 2016 / by / News
CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.
Read more
SolAeroMed Announces Positive Proof-of-Concept Data for Its Lead Drug (S-1226) in Subjects with Mild Atopic Asthma
May 30, 2016 / by / News
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)
Read more